Selection of Microsatellite Markers for Bladder Cancer Diagnosis without the Need for Corresponding Blood

Angela A. G. van Tilborg1, Lucie C. Kompier1, Irene Lurkin1, Ricardo Poort1, Samira El Bouazzaoui1, Kirstin van der Keur1, Tahlita Zuiverloon1, Lars Dyrvskjot2, Torben F. Orntoft2, Monique J. Roobol3, Ellen C. Zwarthoff1*

1 Department of Pathology, Erasmus MC, Rotterdam, The Netherlands, 2 Aarhus University Hospital, Department of Clinical Biochemistry, Skejby, Denmark, 3 Department of Urology, Erasmus MC, Rotterdam, The Netherlands

Abstract

Microsatellite markers are used for loss-of-heterozygosity, allelic imbalance and clonality analyses in cancers. Usually, tumor DNA is compared to corresponding normal DNA. However, normal DNA is not always available and can display aberrant allele ratios due to copy number variations in the genome. Moreover, stutter peaks may complicate the analysis. To use microsatellite markers for diagnosis of recurrent bladder cancer, we aimed to select markers without stutter peaks and a constant ratio between alleles, thereby avoiding the need for a control DNA sample. We investigated 49 microsatellite markers for triand tetranucleotide repeats in regions commonly lost in bladder cancer. Based on analysis of 50 blood DNAs the 12 best performing markers were selected with few stutter peaks and a constant ratio between peaks heights. Per marker upper and lower cut off values for allele ratios were determined. LOH of the markers was observed in 59/104 tumor DNAs. We then determined the sensitivity of the marker panel for detection of recurrent bladder cancer by assaying 102 urine samples of these patients. Sensitivity was 63% when patients were stratified for LOH in their primary tumors. We demonstrate that up-front selection of microsatellite markers obliterates the need for a corresponding blood sample. For diagnosis of bladder cancer recurrences in urine this significantly reduces costs. Moreover, this approach facilitates retrospective analysis of archival tumor samples for allelic imbalance.

Citation: van Tilborg AAG, Kompier LC, Lurkin I, Poort R, El Bouazzaoui S, et al. (2012) Selection of Microsatellite Markers for Bladder Cancer Diagnosis without the Need for Corresponding Blood. PLoS ONE 7(8): e43345. doi:10.1371/journal.pone.0043345

Editor: Masaru Katoh, National Cancer Center, Japan

Received April 2, 2012; Accepted July 19, 2012; Published August 22, 2012

Copyright: © 2012 van Tilborg et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by European Community Seventh Framework program FP7/2007-2012, grant agreement n° 201663; Dutch Cancer Society grant no. EMCR 2007-3863. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: e.zwarthoff@erasmusmc.nl

Introduction

Microsatellite analysis utilizes short, highly polymorphic repeated sequences within the genome. The number of repeats forming a specific microsatellite often varies between the maternal and paternal allele. Microsatellites are used to determine allelic imbalance (AI) or loss-of-heterozygosity (LOH) at particular loci in tumor genomes and can be used as a marker for the presence of tumor cells. To this purpose microsatellite analyses compare the intensity of amplification products of the paternal and the maternal allele from a tumor sample against the ratios from a corresponding normal control (for example leukocytes). When the microsatellite marker is informative (the length of the two alleles differs) the amount of product from both alleles will be the same. On a capillary sequencer this is displayed as two peaks of about equal height. LOH or AI of a chromosomal region in cancer is usually concluded when the ratio between the allele peaks in tumor DNA is smaller than 0.5–0.7 or over 1.5–2 when compared to the control [1,2,3,4].

Bladder cancer (BC) is the fifth most common malignancy in the Western world after breast, prostate, colorectal and lung cancer [5]. More than 70% of primary BC manifest as low grade, non-muscle invasive (pTa, pT1) tumors. After removing these tumors by transurethral resection (TUR), the recurrence rate is high (70%) and many patients will develop multiple metachronous recurrences [6]. Progression from a non-muscle invasive (NMIBC) to a muscle invasive cancer (MIBC) occurs in 10–20% of cases, especially if the original tumor was of high grade [7,8].

At present, the standard procedure for diagnosing BC is cystoscopy. Cystoscopy is an invasive diagnostic approach that is unpleasant for the patient, who has to undergo such controls every 3–12 months for many years after resection of the primary tumor. We estimate that between 1–2 million cystoscopies are being carried out per year in EU and USA for follow up of these patients. Unfortunately, the cytological examination of cells present in voided urine alone does not provide a safe screening alternative for cystoscopy because of its low sensitivity, especially for the detection of low-grade tumors [9]. Similarly, current molecular urine based assays such as fluorescent in situ hybridization (FISH), NMP22 and BTA have sensitivities that are low for the detection of mostly low grade and stage recurrent BC [10,11]. As a result, a number of different molecular analyses on DNA isolated from cells present in voided urine samples have been developed with the goal to improve the sensitivity of detection and to reduce the frequency of invasive cystoscopy examinations. One of these assays involves the detection of mutations in the FGFR3 gene [12]. Mutations in this gene are very frequent in pTa bladder tumors (up to 75% [13,14]). However, this assay is not an option
for detecting tumors without a mutation in this gene, especially since for patients with an FGFR3 wild type primary tumor, the frequency of FGFR3 mutations in recurrences is much lower than for patients with an FGFR3 mutant primary tumor (19% and 81%, respectively) [15].

Many tumors display genomic alterations like gene mutations and numerical aberrations affecting short genomic regions to entire chromosomes. These tumor-specific genomic alterations can be detected by molecular techniques such as FISH [16,17] or by microsatellite analysis (MA). Assays detecting these alterations are proving to be particularly helpful in the identification of cancer patients via noninvasive or little-invasive methods [18,19,20,21]. In bladder cancer for instance, losses of parts of or total chromosome 9 are commonly observed as they arise early in the development of the tumor [22]. Progression of the disease is usually accompanied by additional numerical alterations involving chromosome 8p, 10, and 17p [23,24,25]. We and others have previously shown that the detection of recurrent bladder cancer can be improved by microsatellite analysis of cells obtained from voided urine samples [4,26].

During this work we observed that the PCR products from microsatellites with dinucleotide repeats often had multiple (stutter) peaks due to dissociation of the DNA strands and aberrant reannealing. In addition, many microsatellite markers had aberrant ratios between peak heights in control DNA, possibly due to copy number variations in the genome. Moreover, the need to analyze control blood DNA made the microsatellite assay (MA) expensive [27]. To address these problems more systematically, we have selected tri- and tetranucleotide repeats in genomic regions commonly affected in bladder cancer and designed primers around these repeats for amplification [28]. These new microsatellite markers were then tested for constant peak height ratios and technical performance (i.e. no stutter peaks, fair amplification) in a series of blood DNA samples. The 12 best performing markers were subsequently analyzed in urine DNAs from healthy individuals to determine the cut off values of the ratio of the peak heights in order to obtain a specificity of 95%. Finally, we validated the markers in urine DNAs from patients diagnosed with a recurrent bladder tumor.

**Materials and Methods**

**Samples**

Blood samples were collected from 50 patients with bladder cancer. Urine samples were collected from 106 individuals without history of neoplastic disease. These tumor-negative samples were derived during a screening study in elderly males (over 50 years of age) without previous signs of bladder cancer [29]. DNA from 104 primary tumors was available for LOH analysis. All tumors were non-muscle-invasive (89% Ta, 11% T1). All tumors were grade 1 or 2. Urine samples from patients scheduled for TUR were collected before resection of a histologically proven recurrent tumor from 102 patients. Informed written consent was obtained from all patients, and research protocols were approved by institutional review boards or ethical committees in the two involved countries (the Central Denmark Region Committees on Biomedical Research Ethics Denmark and the The Medical Ethical Committee of the Erasmus MC (METC), the Netherlands). Clinicopathological data for these samples is given in Table S1.

**DNA extraction and LOH analysis**

After collection, the urine was checked for the amount of leukocytes, erythrocytes and nitrite with a dipstick (Siemens Multistix® 10 SG). Cells were pelleted by centrifugation at 3,000 rpm for 10 minutes at 4°C. Cell pellets were washed twice with 10 ml PBS, resuspended in 1 ml PBS, transferred to an Eppendorf vial, and collected by centrifugation for 5 minutes at 6,000 rpm. Supernatant was discarded and the cell pellet was stored at −20°C until DNA isolation. DNA was extracted from blood, tumor tissue (formalin fixed paraffin embedded (FFPE)) and urine and purified with appropriate kits (Qiagen, Hilden, Germany) following instructions of the manufacturer. Concentrations of DNA were measured with a Quant-iT PicoGreen® dsDNA Assay Kit (Molecular Probes, Leiden, The Netherlands).

PCR of different microsatellite markers was performed with separate primer pairs of which 1 oligonucleotide was labeled at the 5’-end with the fluorescent dyes 6-FAM (Invitrogen). Amplification of specific DNA was done in a reaction volume of 15 μl including 0.2 mM dNTPs, 2.5 mM MgCl2, and 0.5 U AmpliTaq. Cycling conditions: 95°C for 5 min, 20 cycles at 95°C for 45 s, 55°C for 45 s, and 72°C for 45 s, followed by a final extension step of 10 min at 72°C. The PCR products were subsequently denatured for 1 min at 95°C in HiDi formamide (Applied Biosystems) and separated on an ABI PRISM 3100 Genetic Analyzer equipped with a 36 cm capillary array loaded with POP-7 polymer. 500-Liz was used as internal size standard (Applied Biosystems). Analysis of the samples was carried out with

---

**In silico selection of microsatellites with tri/tetra nucleotide repeats**

**Select highly informative markers with allele ratios close to 1 on 50 blood DNA samples**

**Determine amount of input DNA and number of cycles**

**Determine cut off values for 95% specificity for each marker on 106 normal urine samples**

**Test LOH/Al of the markers on 104 bladder cancers**

**Determine sensitivity of the markers for detection of recurrent BC on 102 urine DNAs obtained prior to tumor resection**

**Figure 1. Flow chart of the study.**

doi:10.1371/journal.pone.0043345.g001
Figure 2. Overview of the variation between allele ratios for different markers. On the Y-axis, the ratio between the two alleles is given. On the X-axis, the different microsatellite markers are listed. A. The boxplots show that some previously used markers have a large variation in their allele ratio based on an analysis of blood DNA samples from 50 individuals. B. Behavior of the 12 selected markers, indicating they have very little variation in their allele ratio when tested on normal blood and urine from healthy individuals. C. In primary tumor DNA the allele ratio is much more variable due to LOH/AI. 

doi:10.1371/journal.pone.0043345.g002

Table 1. Microsatellite markers selected for this study.

| Marker | Size | Locus | Het | F/R | Sequence |
|--------|------|-------|-----|-----|----------|
| D851109 | 143–167 | 8p | 0.88 | F | TCAGAATTGCTCATAGTGCAAGA |
| D851125 | 221–233 | 8p | 0.69 | F | CCCCTAAATTTATGGCTCA |
| D851130 | 128–148 | 8p | 0.94 | F | GAAGATTTGGGTCGTGTTGA |
| D9S252 | 152–176 | 9q | 0.75 | F | CAAATTTGCGTCGAACCAT |
| D9S299 | 178–198 | 9q | 0.70 | F | AAGTTGGCATCGAGGCTC |
| D9S304 | 135–175 | 9q | 0.86 | F | GTGACCTCTCACAACACAG |
| D9S572 | 178–201 | 9q | 0.73 | F | CAGAGTGTCAGATGAGCTA |
| D9S1118 | 141–177 | 9q | 0.79 | F | GCAAGATGTCAGATGAGCTA |
| D1151981 | 134–178 | 11p | 0.85 | F | AATCTTCTTATTAGCACAGAGG |
| D1151999 | 109–137 | 11p | 0.78 | F | TACATGGCAAGCGCATATA |
| D175697 | 111–132 | 17q | 0.73 | F | ATCTAATCCGTCCATTCACTATCA |
| G10693 | 174–194 | 17p | 0.94 | F | GCAGTCCTCTGGTCACATAGG |

Het: the expected heterozygosity (%) according to the CEPH database (http://www.cephb.fr/en/cephdb/browser.php). F/R: forward or reverse primer.

doi:10.1371/journal.pone.0043345.t001
available, obtained before resection of a recurrent tumor in these patients. Microsatellite assays were performed in duplicate. LOH was assumed when the allele peak ratio of both tests was outside the cut-off values shown in Table 2. Markers D9S752, D9S252, D9S304, D9S299 and G10693 displayed LOH in approximately 20% of the samples (Table 4). Of the 102 samples, 43 samples did not show loss for any of the tested markers. If we assume that false positive tests are not possible since all patients had a recurrence, the sensitivity of the 12 markers together is 58%. Sensitivity according to grade of the primary tumor is given in File S1. The specificity of the test is per definition 100% because all urines were associated with a recurrent tumor. If we selected urines from those patients whose primary tumor had LOH for at least 1 marker, sensitivity for detection of the recurrence in urine DNA increased to 63%. When combined with cytology data, this sensitivity increased to 80% (File S2).

Discussion

In this study we describe an approach to select microsatellite markers for determining copy number and tumor-associated LOH that have an excellent technical performance. The approach was previously used by Frigerio et al., who implemented marker-specific thresholds by assessing normal DNA from blood and control tissue [1]. However, our approach differs in that we preselected our markers for constant allele ratios thereby enhancing accuracy and by the fact that we selected tri- and tetranucleotide repeats that have no or few stutter peaks. By upfront assessing the lower and upper cut-off values based on an analysis of control DNAs, the need to compare patient samples with corresponding blood is therefore avoided. This selection procedure can be applied to any tumor type. This approach also facilitates retrospective analysis of archival tumor samples for allelic imbalance.

We examined the amount of input DNA and the optimal number of PCR cycles. The amount of input DNA is important because too low concentrations may result in preferential amplification of one of the two alleles leading to false positive LOHs [33]. Microsatellite markers are ideal for determining loss or amplification of genomic regions on FFPE-derived DNA because both alleles of a marker will be similarly affected by the quality of the DNA (length) provided that the difference in length between alleles is not too great. Microsatellite analysis is cheap with costs in the order of about 1 euro per assay. For a panel of 10 markers, costs, including DNA isolation, would amount to less than 15 euros. A disadvantage is that microsatellites are not suitable for multiplexing. In our experience this always leads to inefficient amplification of some of the markers and this results in larger standard deviations in duplicate experiments.

Losses on chromosomes 8, 9, 10, 11 and 17 are frequent in bladder cancer and can be detected by microsatellite analysis. This study determines the potential of bladder cancer detection by microsatellite analysis on a set of urine samples collected before transurethral resection of the accompanying tumor (pre-TUR urine). The establishment of marker-specific threshold values based on measurements of allele ratios in urine samples from 106 healthy individuals has allowed us to define the specificity of the method for the subsequent study. Since the individually determined threshold values guaranteed optimal specificity for each of the markers analyzed, we interpreted an LOH at 1 single locus already as indicative for the presence of tumor cells. Applying this rule, we obtained for pre-TUR urine samples an overall sensitivity of 58% for the detection of recurrent tumors and 63% when patients were stratified for LOH in their primary tumor. This sensitivity is comparable to the sensitivity that we previously found with the first set of microsatellite markers even though the new panel of markers was specifically designed to cover for those genomic regions that display LOH in non-muscle invasive bladder tumors (NMIBC). Diagnostic accuracy for the model with all 12 markers was 73% as determined by AUC (Area under the curve). This accuracy was still 73% when only six markers were tested (D9S252, D9S752, D9S304, D8S1125, D8S1130, G10693). With

---

**Table 2.** Upper and lower borders set at 95% specificity based on urine samples from healthy individuals.

| Marker   | Av Ratio | Stddev | 95% interval |
|----------|----------|--------|--------------|
| D8S1109  | 1.09     | 0.08   | 0.93–1.29    |
| D8S1125  | 1.04     | 0.08   | 0.85–1.19    |
| D8S1130  | 1.15     | 0.09   | 1.00–1.40    |
| D9S252   | 1.08     | 0.06   | 0.97–1.23    |
| D9S299   | 1.10     | 0.07   | 0.95–1.27    |
| D9S304   | 1.10     | 0.11   | 0.86–1.33    |
| D9S572   | 1.12     | 0.08   | 0.92–1.31    |
| D9S5118  | 1.10     | 0.10   | 0.97–1.42    |
| D11S1981 | 1.14     | 0.09   | 0.93–1.39    |
| D11S1999 | 1.12     | 0.09   | 0.93–1.45    |
| D17S969  | 1.11     | 0.08   | 0.95–1.33    |
| G10693   | 1.11     | 0.07   | 1.00–1.29    |

---

**Table 3.** Observed heterozygosity and percentage LOH/AI in tumor samples for each marker.

| Marker   | Total | Het% | LOH/AI% |
|----------|-------|------|---------|
| D8S1109  | 103   | 66   | 9       |
| D8S1125  | 104   | 70   | 11      |
| D8S1130  | 104   | 86   | 13      |
| D9S252   | 103   | 77   | 30      |
| D9S299   | 104   | 74   | 29      |
| D9S304   | 103   | 82   | 18      |
| D9S572   | 103   | 80   | 37      |
| D9S5118  | 103   | 86   | 25      |
| D11S1981 | 103   | 88   | 17      |
| D11S1999 | 102   | 87   | 15      |
| D17S969  | 104   | 71   | 9       |
| G10693   | 104   | 72   | 9       |

---

**Microsatellite Analysis without Control DNA**
Table 4. Results of the microsatellite analysis of pre-TUR urine samples.

| Total   | Het% | LOH/AI% |
|---------|------|---------|
| D8S1109 | 102  | 64      | 7       |
| D8S1125 | 102  | 72      | 9       |
| D8S1130 | 102  | 82      | 10      |
| D9S252  | 102  | 79      | 23      |
| D9S299  | 101  | 73      | 20      |
| D9S304  | 102  | 84      | 22      |
| D9S752  | 101  | 84      | 27      |
| D9S1118 | 102  | 88      | 19      |
| D11S1981| 101  | 84      | 9       |
| D11S1999| 102  | 88      | 10      |
| D17S969 | 101  | 71      | 10      |
| G10693  | 102  | 74      | 19      |

doi:10.1371/journal.pone.0043435.t004

this selection, we were able to identify 95% (56 of 59) of all samples showing LOH when tested for all 12 markers. The main advantage of using a smaller selection of microsatellite markers is, next to a reduction in costs, the reduction of the amount of input DNA needed, making this assay also accessible for those samples where only a very limited amount of tissue is available.

In other studies we used mutation analysis of the FGFR3 gene in order to diagnose recurrent tumors [34] [35]. FGFR3 mutations are found in 60–70% of NMIBC and hence provide an ideal tool for surveillance of patients since the mutation assay is 100% specific. Sensitivity, however, depends on the presence of sufficient tumor cells in urine and this is also a caveat for the microsatellite assay. Sensitivity increases when multiple urine samples are analyzed. With a sensitivity of 50% analyzing 2 samples would increase the sensitivity to 75% etc. A combination of microsatellite analysis with the markers presented here and the FGFR3 test is the subject of a longitudinal study on 800 urine samples from 147 patients (Zuiverloon et al., in preparation).

Supporting information

File S1 LOH in pre-TUR urine according to Grade of the primary tumor. (DOCX)

File S2 Comparison of LOH and Cytology on pre-TUR urine samples. (DOCX)

Table S1 Patient data. (XLSX)

Table S2 Details of markers not included in the study. (XLSX)

Author Contributions

Conceived and designed the experiments: EZ TO MR AvT. Performed the experiments: LK II RP SEB KvdK. Analyzed the data: AvT II RP KvdK. Contributed reagents/materials/analysis tools: TZ LD TO MR. Wrote the paper: AvT EZ.

References

1. Frigerio S, Padberg BC, Strebel RT, Lengenhager DM, Meuthaler A, et al. (2007) Improved detection of bladder carcinoma cells in voided urine by standardized microsatellite analysis. Int J Cancer 121: 329–338.
2. van Tilborg AA, de Vries A, de Bont M, Groenfeld LE, van der Kwast TH, et al. (2000) Molecular evolution of multiple recurrent cancers of the bladder. Hum Mol Genet 9: 2973–2980.
3. van Tilborg AA, Heikin AG, Vissers KJ, van der Kwast TH, Zwarthof EC (1998) Loss of heterozygosity on chromosome 9 and loss of chromosome 9 copy number are separate events in the pathogenesis of transitional cell carcinoma of the bladder. Int J Cancer 75: 9–14.
4. van der Aa MN, Zwarthof EC, Seyerberg BW, Boogaard MW, Nijen Y, et al. (2000) Microsatellite Analysis of Voided-Urine Samples for Surveillance of Low-Grade Non-Muscle-Invasive Urothelial Carcinoma: Feasibility and Clinical Utility in a Prospective Multicenter Study (Cost-Effectiveness of Follow-Up of Urinary Bladder Cancer Trial [CEFUB]). Eur Urol.
5. Parkins DM, Bray F, Ferlay J, Pisani P (2000) Global cancer statistics, 2002. CA Cancer J Clin 55: 74–108.
6. Soloway MS, Bruck DS, Kim SS (2003) Expectant management of small, recurrent, noninvasive papillary bladder tumors. J Urol 170: 438–441.
7. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, et al. (2008) EAU Guidelines on Non-Muscle-Invasive Urothelial Carcinoma: Feasibility and Clinical Utility in a Prospective Multicenter Study (Cost-Effectiveness of Follow-Up of Urinary Bladder Cancer Trial [CEFUB]). Eur Urol.
8. van Rhijn BW, van der Poel HG, van der Kwast TH, Soloway MS, Bruck DS, et al. (1998) Loss of heterozygosity on chromosome 9 and loss of chromosome 9 copy number are separate events in the pathogenesis of transitional cell carcinoma of the bladder. Int J Cancer 75: 9–14.
9. van der Aa MN, Zwarthof EC, Seyerberg BW, Boogaard MW, Nijen Y, et al. (2000) Microsatellite Analysis of Voided-Urine Samples for Surveillance of Low-Grade Non-Muscle-Invasive Urothelial Carcinoma: Feasibility and Clinical Utility in a Prospective Multicenter Study (Cost-Effectiveness of Follow-Up of Urinary Bladder Cancer Trial [CEFUB]). Eur Urol.
10. van Rhijn BW, van der Poel HG, van der Kwast TH (2005) Urine markers for bladder cancer surveillance: a systematic review. Eur Urol 47: 736–748.
11. Zwarthoff EC (2008) Detection of tumours of the urinary tract in voided urine. Scand J Urol Nephrol Suppl: 147–153.
12. van Oers JM, Lurkin I, van Exsel AJ, Nijsen Y, van Rhijn BW, et al. (2005) A simple and fast method for the simultaneous detection of nine fibroblast growth factor receptor 3 mutations in bladder cancer and voided urine. Clin Cancer Res 11: 7743–7748.
13. Medeiros LA, Bax A, Assmann K, Assmann K, et al. (2002) FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Ann J Pathol 158: 1955–1959.
14. Cappellen D, De Oliveira C, Ricoli D, de Medina S, Bourdin J, et al. (1999) Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet 23: 18–20.
15. Kompier LC, van der As MN, Lurkin I, Vermeij J, Kirkels WJ, et al. (2008) The development of multiple bladder tumour recurrences in relation to the FGFR3 mutation status of the primary tumour. J Pathol.
16. Placer J, Espinet B, Salido M, Sole F, Gelabert-Mas A (2002) Clinical utility of a multiprobe FISH assay in voided urine specimens for the detection of bladder cancer and in its recurrences, compared with urinary cytology. Uro Eur Urol 42: 547–552.
17. Junker K, Friesch T, Hartmann A, Schulze W, Schuhb J (2006) Multicolor fluorescence in situ hybridization (M-FISH) on cells from urine for the detection of bladder cancer. Cytogenet Genome Res 114: 279–283.
18. Steiner G, Schoenberg MP, Linn JF, Mao L, Sidransky D (1997) Detection of bladder cancer recurrence by microsatellite analysis of urine. Nat Med 3: 621–624.
19. Bortoleti R, Dal Canto M, Gai T, Pizzini M, Travaglini F, et al. (2005) Early diagnosis and monitoring of superficial transitional cell carcinoma by microsatellite analysis on urine sediment. Oncol Rep 13: 531–537.
20. Aboukian DA, Sargent DJ, Loprinzi CL, Levin TR, Rex DK, et al. (2000) Stool DNA and occult blood testing for screen detection of colorectal neoplasia. Annals of Internal Medicine 149: 441–450.
21. Carozzi FM, Bisciotti S, Falini P, Sani C, Venturini G, et al. (2010) Molecular profile in body fluids in subjects enrolled in a randomized trial for lung cancer screening: Perspectives of integrated strategies for early diagnosis. Lung Cancer 68: 216–221.
22. Cairns P, Shaw ME, Knowles MA (1993) Initiation of bladder cancer may involve deletion of a tumour-suppressor gene on chromosome 9. Oncogene 8: 1083–1085.
23. Tsai YC, Nichols PW, Hiti AL, Williams Z, Skinner DG, et al. (1990) Allelic loss of chromosome 9 in a patient with bladder cancer. Cancer Genet Cytogenet 44–47.
24. Tsai YC, Nichols PW, Hiti AL, Williams Z, Skinner DG, et al. (1990) Allelic loss of chromosome 9 in a patient with bladder cancer. Cancer Genet Cytogenet 44–47.
25. Tsai YC, Nichols PW, Hiti AL, Williams Z, Skinner DG, et al. (1990) Allelic loss of chromosome 9 in a patient with bladder cancer. Cancer Genet Cytogenet 44–47.
combination of cytology and standardized microsatellite analysis. Cancer Epidemiol Biomarkers Prev 18: 1798–1806.

27. de Bekker-Grob EW, van der Aa MN, Zwarthoff EC, Eijkemans MJ, van Rhijn BW, et al. (2009) Non-muscle-invasive bladder cancer surveillance for which cystoscopy is partly replaced by microsatellite analysis of urine: a cost-effective alternative? BJU Int 104: 41–47.

28. Koed K, Winf C, Christensen LL, Wikman FP, Zieger K, et al. (2005) High-density single nucleotide polymorphism array defines novel stage and location-dependent allelic imbalances in human bladder tumors. Cancer Res 65: 34–45.

29. Roobol MJ, Bangma CH, El Bouazzaoui S, Franken-Raab CG, Zwarthoff EC (2010) Feasibility study of screening for bladder cancer with urinary molecular markers (the BLU-P project). Urol Oncol 28: 686–690.

30. Mao L, Schoenfeld MP, Sceitchiano M, Erozan YS, Merlo A, et al. (1996) Molecular detection of primary bladder cancer by microsatellite analysis. Science 271: 659–662.

31. van Rhijn BW, Lurkin I, Chopin DK, Kerkels WJ, Thiery JP, et al. (2003) Combined microsatellite and FGFR3 mutation analysis enables a highly sensitive detection of urothelial cell carcinoma in voided urine. Clin Cancer Res 9: 257–263.

32. van Rhijn BW, Lurkin I, Kerkels WJ, van der Kwast TH, Zwarthoff EC (2001) Microsatellite analysis–DNA test in urine competes with cystoscopy in follow-up of superficial bladder carcinoma: a phase II trial. Cancer 92: 768–775.

33. Sieben NL, ter Haar NT, Cornelisse CJ, Fleuren GJ, Cleuton-Jansen AM (2000) PCR artifacts in LOH and MSI analysis of microdissected tumor cells. Hum Pathol 31: 1414–1419.

34. Zuiverloon TC, Tjin SS, Bunstra M, Bangma CH, Beeve ER, et al. (2011) Optimization of Nonmuscle Invasive Bladder Cancer Recurrence Detection Using a Urine Based FGFR3 Mutation Assay. J Urol.

35. Zuiverloon TC, van der Aa MN, van der Kwast TH, Steyerberg EW, Lingsma HF, et al. (2010) Fibroblast growth factor receptor 3 mutation analysis on voided urine for surveillance of patients with low-grade non-muscle-invasive bladder cancer. Clin Cancer Res 16: 3011–3018.